Conference abstract · 29 Jun 2017
Conference abstractPublished 16 Oct 2017
Modern tool of pathogenetic therapy as exemplified in application of antibodies to S100 protein in the released-active form
“NPF ”Materia Medica Holding, Russia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
For mental disorders most commonly applied drugs are benzodiazepines and selective serotonin reuptake inhibitors. However, these drugs have a number of side effects which limit their use in ambulatory practice, especially for people whose profession requires quick mental and motor responses. Furthermore, long-term use of such drugs creates a high risk of mental and physical dependence. Methodology & Theoretical Orientation: The alternative is to correct violations of brain integrative activity. That could be done by modulating the functions of endogenous regulatory molecules, for example, those of S100 protein. It is involved in the pathogenesis of different psychiatric disorders. S100 function can be influenced by the use of antibodies. Modulation of S100 proteins’ functions is a key mechanism of action of Tenoten® and Divaza® – drugs presented on Russian and CIS pharmaceutical markets. As the active pharmaceutical ingredient they contain antibodies to S100 in released-active form (RA anti-S100) produced by ultra-high dilution technology. It was found that these types of drugs can modify conformation of their targets and thereby change the strength of ligand-receptor interaction. Spectrum of RA anti-S100 pharmacological activity has been shown in the numerous experimental and clinical studies. Findings: It has been proved that RA anti-S100 have anxiolytic, antidepressant, anti-stress, anti-aggressive, nootropic (anti-amnestic neuroprotective) and neurotrophic activities without sedative and muscle relaxant effects and any type of dependence. Conclusion & Significance: Treatment with drugs containing released-active forms of antibodies to S100 protein is modern tool of pathogenetic therapy.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 29 Dec 2016
Released-active antibodies: Breakthrough concept of antibodies-based therapeutics
Conference abstract · 2 Jul 2018
Protein binders mimicking surface glycoprotein epitopes recognized by broadly neutralizing antibodies as a new platform for identification of peptide-prints as tools for development of more protective vaccines
Conference abstract · 1 Jun 2017
Antibodies and Protein Engineering 2017: The gene expression evidence-base and its relevance to translational applications including prevention- Ron L Martin, Nutrigenetics Unlimited Inc.
Commentary · 20 Sep 2024
Monoclonal Antibodies: Precision Tools in Modern Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectImmunology & Microbiology
- SubjectMicrobiology
- BylineArticles whose byline prints “Gulnara Kahakimova”
